An international study by Kosiborod et al. conducted in patients with T2DM from the Asia Pacific, the Middle East, and North America, comparing SGLT2 inhibitors and other glucose-lowering drugs, showed a significant reduction in hospitalization due to HF, the incidence of myocardial infarction (MI), and all-cause mortality [16]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.